TB-500

A research peptide often sold under a name that overlaps with thymosin beta-4. It is not an FDA-approved drug.

Why it is trending: public search and clinic marketing have moved faster than a settled human evidence base. This page does not score that attention as benefit or safety.

Human evidence

Human evidence is very limited for a consumer conclusion, except where an approved labeling exists for a specific indication. This review does not invent trial results.

Preclinical evidence

Animal and laboratory papers exist for several of these compounds. Preclinical work does not establish human effectiveness.

Risks and unknowns

Known risks include an incomplete human safety picture and, outside regulated manufacturing, uncertain product identity. Major unknowns include long-term safety, standardized human dosing, and clinical effectiveness.

Reviewed 24 September 2026. Regulatory status can change. Check the FDA record before treating any sentence here as current law.